Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DM-101PX in Birch Pollen Allergy
NCT07898800Phase 1Recruiting
- Sponsor
- Desentum
- Start
- Oct 2026
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DM-101 in birch pollen allergy (8 cohorts), sponsored by Desentum. Primary endpoints: Treatment Emergent Adverse Events at 3 months and Adverse Events of Special Interest at 3 months. Started Oct 2026; status: recruiting.
02
Drugs
DM-101
03
Conditions
birch pollen allergy
Beyond the preview
Go deeper on NCT07898800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07898800.